Programmable Ru(II) phototherapeutics: master dials, mode switches, and coligand-controlled reactivity

The ability to program excited-state pathways in Ru(II) polypyridyl complexes offers a powerful strategy for controlling phototherapeutic activity, yet how reliably such design principles translate across biological contexts remains unclear. In this work, we examine how systematic modulation of ligand structure alters excited-state accessibility and biological response across multiple test systems. Specifically, we investigate a complete series of oligothiophene-extended Ru(II) complexes, Ru(6, 6′-dmb)2(IP-nT) series (n = 0–4), using spectroscopy, computation, photochemistry, and photobiology to define how oligothiophene length and coligand environment govern excited-state accessibility and biological response. Increasing oligothiophene chain length progressively suppresses photodissociative 3MC pathways in favor of stabilized nT-centered 3ILCT states. In mammalian cancer cells, only Ru-3T and Ru-4T exhibit light-dependent cytotoxicity, with Ru-4T emerging as the most effective compound under both normoxic and hypoxic conditions despite similar singlet-oxygen yields and triplet lifetimes. Antibacterial studies reveal additional biological constraints: while Ru-4T displays light-selective activity in Staphylococcus aureus, responses are attenuated in Enterococcus faecalis and absent in Gram-negative bacteria. Preliminary in vivo tolerability studies show that Ru-4T is well tolerated and exhibits reduced systemic toxicity relative to related analogues. Together, these results demonstrate that stabilized ILCT-based excited states, rather than 3MC-driven photochemistry, underpin productive phototherapeutic activity in this family of compounds, while biological context ultimately defines the limits of predictability for excited-state design.